Peptide Comparison
GanirelixvsTriptorelin
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
At a Glance
Quick
comparison
Dose Range
Ganirelix
250 mcg–500 mcg micrograms
Triptorelin
0.1 mg–22.5 mg mg
Frequency
Ganirelix
Once daily
Triptorelin
Once daily
Administration
Ganirelix
Subcutaneous injection
Triptorelin
Intramuscular injection
Cycle Length
Ganirelix
Ongoing/indefinite
Triptorelin
Ongoing/indefinite
Onset Speed
Ganirelix
Moderate (1-2 weeks)
Triptorelin
Moderate (1-2 weeks)
Evidence Level
Ganirelix
Strong human trials (Phase 3 or FDA approved)
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Ovulation Control
IVF Success Improvement
Safety & OHSS Prevention
Hormone Regulation
Cancer Management
Endometriosis Relief
Technical Data
Compound
specifications
Ganirelix
Molecular Formula
C80H113ClN18O13
Molecular Weight
1570.4 g/mol
Half-Life
10-12 hours
Bioavailability
~91% (subcutaneous injection)
CAS Number
124904-93-4
Triptorelin
Molecular Formula
C64H82N18O13
Molecular Weight
1311.4 g/mol
Half-Life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS Number
57773-63-4
Applications
Best
suited for
Ganirelix
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Ganirelix
Common
- Mild discomfort at treatment site
- Injection site reactions (redness, bruising, swelling)
- Headaches
- Abdominal pain
- Pelvic discomfort
- Nausea
- Fatigue or dizziness
Serious
- Severe allergic reaction
Triptorelin
Research Status
Safety
& evidence
Ganirelix
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted.
Contraindications
- xPregnancy or suspected pregnancy
- xBreastfeeding
- xKnown allergies to any medication component
- xOvarian cysts larger than 3cm
Triptorelin
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- xPregnancy (can affect fetal development)
- xUndiagnosed vaginal bleeding
- xKnown hypersensitivity to GnRH agonists
- xSevere untreated depression
- xActive spinal cord compression in prostate cancer (requires urgent decompression)
Decision Guide
Which is
right for you?
Choose Ganirelix if...
- Improving IVF or ICSI success rates
- Preventing premature ovulation during egg retrieval cycles
- Controlling ovarian stimulation in women with unpredictable cycles
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation